SecBot SecBot
Biotech Drug Report Generated Oct 24, 2026

quemliclustat

RCUS·Arcus Biosciences, Inc.
NEUTRAL
Drug Impact Rating6/10
Trial phase
Phase 2
Time to market
At least 4-6 years minimum. Quemliclustat is in Phase 2 testing with primary completion estimated January 2027. If successful, it would need to advance to Phase 3 and then regulatory filing, putting potential approval/commercialization at least several years away.
Why 6/10
The next hard catalyst for quemliclustat's next dated binary catalyst is the Phase 2 primary completion readout from trial NCT05329766 (estimated primary completion January 2027). This is ~3 months away, but quemliclustat is a secondary asset in Arcus's pipeline behind casdatifan, so the impact on RCUS stock from this single drug is moderate.
⚠ Few sources Few sources were found for this drug. Treat the rating as low-confidence and verify against the cited sources.
Actionable Insight NEUTRAL

The next hard catalyst for quemliclustat is the Phase 2 primary completion readout from trial NCT05329766, estimated for January 2027. However, this is a secondary pipeline asset at Arcus, the stock's primary value driver is casdatifan (HIF-2α inhibitor). Watch for topline data from the GI malignancy trial in early 2027, but expect the stock to move more on casdatifan and domvanalimab catalysts than on quemliclustat alone.

Price Chart

Loading chart...

Executive Summary

Quemliclustat is a Phase 2 small-molecule CD73 inhibitor being developed by Arcus Biosciences (RCUS) for advanced upper gastrointestinal tract malignancies. It is being tested in a 332-patient Phase 2 trial (NCT05329766) in combination with domvanalimab (anti-TIGIT), zimberelimab (anti-PD-1), and FOLFOX chemotherapy. The trial is active but not recruiting, with estimated primary completion in January 2027. Quemliclustat is a secondary pipeline asset at Arcus, the company's lead program is casdatifan (HIF-2α inhibitor), which received the majority of a recent $250M capital raise. The stock trades at $18.54 with strong analyst support (mean PT $41, ~121% upside) and elevated short interest (~10.3% of outstanding).

How It Works

Quemliclustat is a small-molecule drug that blocks an enzyme called CD73, which tumors use to produce adenosine, a substance that suppresses the immune system's ability to attack cancer. By inhibiting CD73, the drug aims to remove this 'immune brake, allowing other immunotherapies (like checkpoint inhibitors) and chemotherapy to work more effectively.

Trial Status

Quemliclustat is being evaluated in a single Phase 2 trial (NCT05329766) for advanced upper GI tract malignancies. The trial started June 2022, enrolled 332 patients, and is now active but not recruiting. No results have been posted yet. Estimated primary completion is January 2027 (primary) and overall completion June 2027.

The Two-Sided Case

▲ Bull Case4
Quemliclustat is being tested in a rational combination with domvanalimab (anti-TIGIT) and zimberelimab (anti-PD-1) plus chemotherapy, a multi-pronged immunotherapy approach targeting multiple immune checkpoints and the adenosine pathway simultaneously.
The Phase 2 trial (NCT05329766) is fully enrolled (332 patients) and active but not recruiting, meaning data collection is underway with estimated primary completion in January 2027.
Arcus has strong analyst support, 16 Buy/Strong Buy ratings vs 0 Sell, with a mean price target of $41 (121% upside from $18.54), suggesting the market sees value in the broader pipeline including quemliclustat.
Short interest of ~10.3% of outstanding shares with 7.64 days to cover could amplify any positive catalyst.
▼ Bear Case4
Quemliclustat is a secondary pipeline asset at Arcus, the company's primary focus and capital allocation is on casdatifan (HIF-2α inhibitor), which received the bulk of the $250M October 2026 offering proceeds. Quemliclustat may be deprioritized if casdatifan requires more resources.
The Phase 2 trial (NCT05329766) has no posted results yet and the estimated primary completion is January 2027, nearly 5 years after trial start in June 2022, suggesting enrollment or data collection challenges.
CD73 inhibitors as a class have faced mixed clinical results across the industry, with several programs failing to show clear benefit over standard-of-care checkpoint inhibitors.
Arcus has a high cash burn rate (~$182M/quarter) and just raised $250M at an 8.4% discount, indicating ongoing dilution risk for shareholders.

Upcoming Catalysts

  • Phase 2 primary completion readout from NCT05329766 (estimated January 2027)
  • Potential data presentations at medical conferences in 2026-2027
  • Any pipeline prioritization updates from Arcus (R&D day, quarterly earnings updates)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Arcus Biosciences, Inc. 8-K RCUS ·Originating report

Sources · 1

Hover a chip for the title
1 sec.gov